<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311090</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5945</org_study_id>
    <secondary_id>2005-005326-30</secondary_id>
    <nct_id>NCT00311090</nct_id>
  </id_info>
  <brief_title>Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs</brief_title>
  <acronym>EQUINOX</acronym>
  <official_title>International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The three purposes of this study are the following:

        -  To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux
           (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep
           venous thrombosis (DVT) and pulmonary embolism (PE), and bleeding risk;

        -  To compare the activities of idrabiotaparinux and idraparinux directly in blood during
           and after a 6-month treatment;

        -  To check the ability of avidin (SSR29261) to reverse the blood thinning activity of
           idrabiotaparinux at the end of a 6-month treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists in a 6-month treatment period followed by an observational period of 3 to
      6 months with a month 9 visit and a phone/contact visit at month 12.

      All participants who complete the 6-month treatment period are re-randomized to either the
      idrabiotaparinux/idraparinux bioequipotency sub-study or the avidin neutralizing effect
      sub-study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequipotency sub-study: idrabiotaparinux/idraparinux ratio for pharmacodynamic exposure parameters</measure>
    <time_frame>Day 183</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Avidin neutralizing effect substudy: decrease in anti-Xa activity between the start and end of the avidin infusion</measure>
    <time_frame>Day 183 to Day 188</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile: idrabiotaparinux and idraparinux plasma concentrations</measure>
    <time_frame>Days 15, 36, 57, 92 and 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: number of participants with clinically relevant bleedings and number of deaths as confirmed by a Central Independent Adjudication Committee (CIAC)</measure>
    <time_frame>First 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: number of participants with symptomatic recurrent venous thromboembolism as confirmed by the CIAC</measure>
    <time_frame>First 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">757</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Idrabiotaparinux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.
In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idraparinux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Idraparinux sodium, 2.5 mg, once-weekly for 6 months
In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idrabiotaparinux sodium</intervention_name>
    <description>0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection</description>
    <arm_group_label>Idrabiotaparinux</arm_group_label>
    <other_name>Biotinylated Idraparinux</other_name>
    <other_name>SSR126517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idraparinux sodium</intervention_name>
    <description>0.5 mL pre-filled syringe for 2.5 mg
Subcutaneous injection</description>
    <arm_group_label>Idraparinux</arm_group_label>
    <other_name>SR34006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avidin</intervention_name>
    <description>100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes</description>
    <arm_group_label>Idrabiotaparinux</arm_group_label>
    <other_name>SSR29261</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Avidin)</intervention_name>
    <description>Avidin matching powder in 10 mg/mL solution
Intravenous infusion for 30 minutes</description>
    <arm_group_label>Idrabiotaparinux</arm_group_label>
    <arm_group_label>Idraparinux</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed acute symptomatic DVT of the lower limbs

        Exclusion Criteria:

          -  Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled
             hypertension)

          -  Active bleeding or high risk for bleeding.

          -  Pregnancy or childbearing potential without proper contraceptive measures.

          -  Breastfeeding

          -  Known allergy to idraparinux, SSR126517E, or egg proteins

          -  Indication of prolonged anticoagulation for other reason than DVT of the lower limbs

          -  Symptomatic pulmonary embolism (PE)

          -  Life expectancy &lt; 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Macquarie Park</city>
        <zip>NSW 2113</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Diegem</city>
        <zip>1831</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05677-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <zip>H7L 4A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Praha</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Israel</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Mexico</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis, Netherlands</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>New Zealand</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsawa</city>
        <zip>02-672</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Moscow</city>
        <zip>103045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Midrand</city>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <zip>08019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Turkey</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </removed_countries>
  <results_reference>
    <citation>Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost. 2011 Jan;9(1):92-9. doi: 10.1111/j.1538-7836.2010.04100.x.</citation>
    <PMID>20946157</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <disposition_first_submitted>February 19, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 19, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 21, 2016</disposition_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Venous Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biotin</mesh_term>
    <mesh_term>SANORG 34006</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

